China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy company after the transaction closes, ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

(Reuters) -U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental ...

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio for SSGJ-707.

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech ...